Home › Chronic Kidney Disease › NCT06694558
Monocytes in Subjects With Type 1 Diabetes and Chronic Kidney Disease
RecruitingObservational study
Who can join
Ages 18 to 65 · All sexes
Full eligibility criteria
Inclusion Criteria: 1. T1D CKD subjects: 1. Adults, males or females diagnosed with T1D 2. Age 18-65 years 3. Diagnosed with CKD (eGFR 60-90 ml/min/1.73 m2) 4. Diagnosed with albuminuria (UACR 30-500 mg/g) 5. On insulin injections or pump 6. On CGM Based on baseline CGM metrics, the investigators will stratify subjects to 2 groups Group A (Lower TIR group): TIR\<60%, A1c 7.5-9.5 Group B (Higher TIR group): TIR\>70% A1c 5.0-7.0 2. Controls: T1D subjects without CKD 1. Adults, males or females diagnosed with T1D 2. Age 18-65 years 3. No CKD (eGFR \>90 ml/min/1.73 m2) 4. No albuminuria (UACR \<30 mg/g) 5. On insulin injections or pump 6. On CGM Based on baseline CGM metrics, the investigators will stratify subjects to 2 groups Group A (Lower TIR group): TIR\<60%, A1c 7.5-9.5 Group B (Higher TIR group): TIR\>70% A1c 5.0-7.0 Exclusion Criteria: 1. Hemoglobin \<9 2. On GLP-1 agonist or DPP4 inhibitor or sodium-glucose co-transporter-2 inhibitors use within 30 days 3. pregnancy or plans to become pregnant 4. On steroids 5. Diagnosed with cancer, immunosuppression/autoimmune conditions 6. Reported heavy alcohol use or recreational drug use 7. Any condition which jeopardizes patient safety or affects monocytes at physician's discretion
About the study
This is a cross-sectional study in patients with Type 1 diabetes (TID) and chronic kidney disease (CKD) to test if time in range (TIR) affects the degree of hyperglycemia required for monocyte activation, podocyte injury, and assess if monocyte activation is attenuated by glucagon-like peptide (GLP-1) agonist treatment ex vivo.
Sponsor: The Cleveland Clinic · Participants: 60 · Started: Mar 1, 2025
Contact the study team
- Andrea Debs · Phone: 216-445-8354
Official record on ClinicalTrials.gov — NCT06694558
Locations in the U.S.
| Ohio | Cleveland Clinic, Cleveland |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.